BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 33053560)

  • 21. Final results of DIADEM, a phase II study to investigate the efficacy and safety of durvalumab in advanced pretreated malignant pleural mesothelioma.
    Canova S; Ceresoli GL; Grosso F; Zucali PA; Gelsomino F; Pasello G; Mencoboni M; Rulli E; Galli F; De Simone I; Carlucci L; De Angelis A; Belletti M; Bonomi M; D'Aveni A; Perrino M; Bono F; Cortinovis DL;
    ESMO Open; 2022 Dec; 7(6):100644. PubMed ID: 36463732
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study.
    Park SJ; Kim H; Shin K; Hong TH; Suh JH; Lee MA
    BMC Cancer; 2021 Nov; 21(1):1176. PubMed ID: 34732161
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment patterns and outcomes of patients with advanced malignant pleural mesothelioma in a community practice setting.
    Waterhouse DM; Nwokeji ED; Boyd M; Penrod JR; Espirito JL; Robert NJ; Daumont MJ
    Future Oncol; 2021 Jul; 17(19):2439-2448. PubMed ID: 33769073
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effectiveness and safety of platinum-based pemetrexed and platinum-based gemcitabine treatment in patients with malignant pleural mesothelioma.
    Ak G; Metintas S; Akarsu M; Metintas M
    BMC Cancer; 2015 Jul; 15():510. PubMed ID: 26156324
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naïve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905).
    Tsao AS; Miao J; Wistuba II; Vogelzang NJ; Heymach JV; Fossella FV; Lu C; Velasco MR; Box-Noriega B; Hueftle JG; Gadgeel S; Redman MW; Gandara DR; Kelly K
    J Clin Oncol; 2019 Oct; 37(28):2537-2547. PubMed ID: 31386610
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial.
    Forde PM; Anagnostou V; Sun Z; Dahlberg SE; Kindler HL; Niknafs N; Purcell T; Santana-Davila R; Dudek AZ; Borghaei H; Lanis M; Belcaid Z; Smith KN; Balan A; White JR; Cherry C; Ashok Sivakumar IK; Shao XM; Chan HY; Singh D; Thapa S; Illei PB; Pardoll DM; Karchin R; Velculescu VE; Brahmer JR; Ramalingam SS
    Nat Med; 2021 Nov; 27(11):1910-1920. PubMed ID: 34750557
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SELECT-3: a phase I study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting.
    Greystoke A; Steele N; Arkenau HT; Blackhall F; Md Haris N; Lindsay CR; Califano R; Voskoboynik M; Summers Y; So K; Ghiorghiu D; Dymond AW; Hossack S; Plummer R; Dean E
    Br J Cancer; 2017 Sep; 117(7):938-946. PubMed ID: 28950288
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma.
    Zucali PA; Perrino M; Lorenzi E; Ceresoli GL; De Vincenzo F; Simonelli M; Gianoncelli L; De Sanctis R; Giordano L; Santoro A
    Lung Cancer; 2014 Jun; 84(3):265-70. PubMed ID: 24321581
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Induction chemotherapy, extrapleural pneumonectomy (EPP) and adjuvant hemi-thoracic radiation in malignant pleural mesothelioma (MPM): Feasibility and results.
    Rea F; Marulli G; Bortolotti L; Breda C; Favaretto AG; Loreggian L; Sartori F
    Lung Cancer; 2007 Jul; 57(1):89-95. PubMed ID: 17403553
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Systemic treatment in patients with malignant pleural mesothelioma - real life experience.
    Ziółkowska B; Cybulska-Stopa B; Papantoniou D; Suwiński R
    BMC Cancer; 2022 Apr; 22(1):432. PubMed ID: 35443624
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pemetrexed plus platinum or gemcitabine plus platinum for advanced non-small cell lung cancer: final survival analysis from a multicentre randomized phase II trial in the East Asia region and a meta-analysis.
    Zhang X; Lu J; Xu J; Li H; Wang J; Qin Y; Ma P; Wei L; He J
    Respirology; 2013 Jan; 18(1):131-9. PubMed ID: 22882698
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ganetespib in Combination with Pemetrexed-Platinum Chemotherapy in Patients with Pleural Mesothelioma (MESO-02): A Phase Ib Trial.
    Fennell DA; Danson S; Woll PJ; Forster M; Talbot D; Child J; Farrelly L; Sharkey A; Busacca S; Ngai Y; Hackshaw A; Wheeler GM
    Clin Cancer Res; 2020 Sep; 26(18):4748-4755. PubMed ID: 32669375
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term results in malignant pleural mesothelioma treated with neoadjuvant chemotherapy, extrapleural pneumonectomy and intensity-modulated radiotherapy.
    Thieke C; Nicolay NH; Sterzing F; Hoffmann H; Roeder F; Safi S; Debus J; Huber PE
    Radiat Oncol; 2015 Dec; 10():267. PubMed ID: 26715491
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma.
    Zauderer MG; Kass SL; Woo K; Sima CS; Ginsberg MS; Krug LM
    Lung Cancer; 2014 Jun; 84(3):271-4. PubMed ID: 24690410
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression of the Stem Cell Factor Nestin in Malignant Pleural Mesothelioma Is Associated with Poor Prognosis.
    Thies S; Friess M; Frischknecht L; Korol D; Felley-Bosco E; Stahel R; Vrugt B; Weder W; Opitz I; Soltermann A
    PLoS One; 2015; 10(9):e0139312. PubMed ID: 26421614
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial.
    Ceresoli GL; Aerts JG; Dziadziuszko R; Ramlau R; Cedres S; van Meerbeeck JP; Mencoboni M; Planchard D; Chella A; Crinò L; Krzakowski M; Rüssel J; Maconi A; Gianoncelli L; Grosso F
    Lancet Oncol; 2019 Dec; 20(12):1702-1709. PubMed ID: 31628016
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination chemotherapy with irinotecan and gemcitabine for taxane/platinum-resistant/refractory ovarian and primary peritoneal cancer: a multicenter phase I/II trial (GOGO-Ov 6).
    Yoshino K; Kamiura S; Yokoi T; Nakae R; Fujita M; Takemura M; Adachi K; Wakimoto A; Nishizaki T; Shiki Y; Tsutsui T; Kanda Y; Kobayashi E; Hashimoto K; Mabuchi S; Ueda Y; Sawada K; Tomimatsu T; Kimura T
    Cancer Chemother Pharmacol; 2017 Dec; 80(6):1239-1247. PubMed ID: 29080971
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Successful salvage chemotherapy with gemcitabine and vinorelbine in a malignant pleural mesothelioma patient previously treated with pemetrexed.
    Agatsuma T; Koizumi T; Yasuo M; Urushihata K; Tsushima K; Yamamoto H; Hanaoka M; Fukushima M; Honda T; Kubo K
    Jpn J Clin Oncol; 2010 Dec; 40(12):1180-3. PubMed ID: 20603247
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [A phase I study of gemcitabine and irinotecan as second line treatment for advanced non-small cell lung cancer].
    Ryo H; Toyama K; Isobe K; Sugino K; Sano G; Yamada H; Hiroi M; Hojyo T; Kimura K
    Gan To Kagaku Ryoho; 2003 Feb; 30(2):237-42. PubMed ID: 12610872
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment patterns and outcomes in older patients with advanced malignant pleural mesothelioma: Analyses of Surveillance, Epidemiology, and End Results-Medicare data.
    Danese MD; Daumont M; Nwokeji E; Gleeson M; Penrod JR; Lubeck D
    Cancer Rep (Hoboken); 2022 Sep; 5(9):e1568. PubMed ID: 34698447
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.